Aidea Pharma: Ainomit Tablets Obtains Drug Registration Certificate in Zanzibar
Aidea Pharma recently obtained the Drug Registration Certificate for Ainomi Tablets issued by the Zanzibar Food and Drug Authority. This drug is a compound anti-HIV-1 infection chemical drug developed independently by the company, based on the novel non-nucleoside reverse transcriptase inhibitor Ainovelin Tablets, which includes two nucleoside reverse transcriptase inhibitors: fumarate tenofovir disoproxil and lamivudine
According to the announcement from Aidea Pharma (688488.SH), the company recently received the Drug Registration Certificate for Ainomi Tablets approved by the Zanzibar Food and Drug Administration on July 25, 2025.
The announcement indicates that Ainomi Tablets are a Class 1 new drug developed by the company with independent intellectual property rights, which is a compound anti-HIV-1 infection chemical drug in a single tablet form. It is based on the company's Class 1 new drug for anti-HIV-1 infection—Ainovelin Tablets (brand name: Aibond®), to which two nucleoside reverse transcriptase inhibitors (NRTIs)—tenofovir disoproxil fumarate (TDF) and lamivudine (3TC)—have been added to create a compound formulation
